Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Membrane Protein > CD20 > CHEK-ATP034

HEK293/Human CD20 Stable Cell Line

  • Description

    HEK293/Human CD20 Stable Cell Line

  • Application

    Binding assay by FACS and cell based ELISA.

  • Growth Properties

    Adherent

  • Selection Marker

    Puromycin (5 μg/mL)

  • Culture Medium

    DMEM medium + 10% FBS

  • Freeze Medium

    10% DMSO + 90% FBS

  • Format/Supplied As

    1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.

  • Storage

    Frozen in liquid nitrogen

  • Instructions for Use

    See data sheet for detailed culturing protocol

Receptor Assay
Receptor Assay

FACS assay shows that Monoclonal Anti-Human CD20 Full Length Antibody, Human IgG1 can bind to HEK293/Human CD20 Stable Cell Line. HEK293/Human CD20 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).

  • Background
    B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $6900.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:23 Details
  • Number of Drugs in Clinical Trials:81 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message